EP0706376B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Anti-angiogenic compositions and methods of use
Assignee: Angiotech Pharmaceuticals Inc
•
Filing: 1994-07-19
•
Granted: 1997-06-25
•
Expires: 2014-07-19
Abstract
Abstract The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
Inventors
- 👤 Helen M. Burt
- 👤 William L. Hunter
- 👤 Lindsay S. Machan
- 👤 A. Larry Arsenault
- 👤 John K. Jackson
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 17:44
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K33/00; A61K33/24; A61K31/12; A61K31/122; A61K31/13; A61K31/135; A61K31/136; A61K31/16; A61K31/165; A61K31/203; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/41; A61K31/425; A61K31/426; A61K31/427; A61K31/435; A61K31/47; A61K31/4738; A61K31/4745; A61K31/495; A61K31/505; A61K31/519; A61K31/525; A61K31/555; A61K31/56; A61K31/565; A61K31/57; A61K31/70; A61K31/702; A61K33/06; A61K33/30; A61K38/00; A61K38/16; A61K38/55; A61K38/57; A61K45/00; A61K45/06; A61K9/0012; A61K9/0019; A61K9/0048; A61K9/0051; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1635; A61K9/1641; A61K9/1647; A61K9/1658; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5031; A61K9/51; A61K9/5107; A61K9/513; A61K9/5146; A61K9/5153; A61K9/70; A61K9/7007; A61L; A61L31/00; A61L31/08; A61L31/10; A61L31/14; A61L31/145; A61L31/16; A61P; A61P1/00; A61P1/04; A61P1/16; A61P11/00; A61P13/00; A61P13/02; A61P19/00; A61P19/02; A61P27/00; A61P27/02; A61P35/00; A61P43/00; A61P7/00; A61P7/02; A61P7/04; A61P9/00; A61P9/10; A61P9/14; C; C07; C07C; C07C233/00; C07C233/64; C07K; C07K14/00; C07K14/81; C07K14/8107; C07K14/811; C08; C08L; C08L23/00; C08L23/02; C08L23/04; C08L23/08; C08L23/0846; C08L23/0853; C08L67/00; C08L67/04; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/606; A61L2300/62; A61L2300/622; A61L2430/00; A61L2430/36; B; B82; B82Y; B82Y5/00; C08L2203/00; C08L2203/02; C08L2312/00; C08L29/00; C08L29/02; C08L29/04; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/773; Y10S977/902; Y10S977/904; Y10S977/915
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
27 words
A stent for expanding the lumen of a body passageway, comprising a generally tubular structure coated with a composition comprising an anti-angiogenic factor and a polymeric carrier.
Claim 2
Dependent Claim
14 words
A stent according to claim 1 wherein said anti-angiogenic factor is a chemotherapeutic agent.
Claim 3
Dependent Claim
20 words
A stent according to claim 1 wherein said anti-angiogenic factor is selected from the group consisting of estramustine and methotrexate.
Claim 4
Dependent Claim
18 words
A stent according to claim 1 wherein said anti-angiogenic factor is taxol, or an analogue or derivative thereof.
Claim 5
Dependent Claim
18 words
A stent according to any one of claims 1 to 4 wherein said polymeric carrier comprises poly (caprolactone).
Claim 6
Dependent Claim
19 words
A stent according to any one of claims 1 to 4 wherein said polymeric carrier comprises poly (lactic acid).
Claim 7
Dependent Claim
19 words
A stent according to any one of claims 1 to 4 wherein said polymeric carrier comprises poly (ethylene-vinyl acetate).
Claim 8
Dependent Claim
25 words
A stent according to any one of claims 1 to 4 wherein said polymeric carrier comprises a copolymer of poly caprolactone and poly lactic acid.
Claim 9
Dependent Claim
18 words
A stent according to any one of claims 1 to 8 wherein said stent is a vascular stent.
Claim 10
Dependent Claim
18 words
A stent according to any one of Claims 1 to 8 wherein said stent is a biliary stent.
Claim 11
Dependent Claim
18 words
A stent according to any one of Claims 1 to 8 wherein said stent is a urethral stent.
Claim 12
Dependent Claim
18 words
A stent according to any one of Claims 1 to 8 wherein said stent is a esophageal stent.
Claim 13
Dependent Claim
18 words
A stent according to any one of Claims 1 to 8 wherein said stent is a tracheal/bronchial stent.
Claim 14
Dependent Claim
18 words
A stent according to any one of Claims 1 to 8 for treating narrowing of a body passageway.
Claim 15
Dependent Claim
12 words
A stent according to Claim 14 for treating or preventing recurrent stenosis.
Claim 16
Dependent Claim
17 words
Use of a composition comprising an anti-angiogenic factor for the manufacture of a medicament for treating arthritis.
Claim 17
Dependent Claim
17 words
Use according to Claim 16 wherein said anti-angiogenic factor is taxol, or an analogue or derivative thereof.
Claim 18
Dependent Claim
16 words
Use according to Claims 16 or 17 wherein said anti-angiogenic factor further comprises a polymeric carrier.
Claim 19
Dependent Claim
12 words
Use according to Claim 18 wherein said polymeric carrier comprises poly (caprolactone).
Claim 20
Dependent Claim
13 words
Use according to claim 18 wherein said Polymeric carrier comprises poly (lactic acid).
Claim 21
Dependent Claim
13 words
Use according to claim 18 wherein said polymeric carrier comprises poly (ethylene-vinyl acetate).
Claim 22
Dependent Claim
13 words
Use according to claim 18 wherein said polymeric carrier comprises poly (lactic-co-glycolic) acid.
Claim 23
Dependent Claim
14 words
Use according to any one of claims 16-23 wherein said arthritis is inflammatory arthritis.
Claim 24
Dependent Claim
19 words
Use according to any one of claims 16-23 wherein said arthritis is treated by intra-articular administration of said medicament.
Claim 25
Dependent Claim
22 words
Use of a composition comprising an anti-angiogenic factor and a polymeric carrier for coating a stent according to anyone of claims 1-15.
Claim 26
Dependent Claim
17 words
Use of taxol, or an analogue or derivative thereof, for the manufacture of a medicament for anti-angiogenesis.
Claim 27
Dependent Claim
12 words
Use according to Claim 26 wherein said medicament is for treating psoriasis.
Claim 28
Dependent Claim
13 words
Use according to Claim 26 wherein said medicament is for treating vascular adhesions.
Claim 29
Dependent Claim
17 words
A stent according to any one of Claims 1 to 4 wherein said polymeric carrier comprises gelatin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.